Is the AstraZeneca share price still good value at £10?

The AstraZeneca share price has been a top FTSE 100 performer in recent years. Roland Head asks if he’s too late to buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

FTSE 100 pharmaceutical giant AstraZeneca (LSE: AZN) has seen its share price rise by around 25% over the last 12 months. AstraZeneca shares have now doubled over the last five years.

Its growth has accelerated under chief executive Pascal Soriot. I’d like to own a slice of this market-leading business, but I need to be sure there’s still some value left for me. Here’s what I’ve decided.

Strong momentum

The Anglo-Swedish group’s sales rose by 26% to $33.4bn in 2021, excluding around $4bn of revenue from Covid-19 vaccine sales. I’ve ignored this as I don’t see this product as part of the firm’s ongoing business. At least, I hope it won’t be.

This revenue growth supported a 32% rise in adjusted earnings, which rose to $5.29 per share.

Soriot says the company had 13 blockbuster medicines in 2021 – those with sales of more than $1bn. This list included two new ones, Calquence and Fasenra.

These numbers suggest to me that Mr Soriot’s strategy of pursuing acquisitions alongside in-house drug development is really starting to pay off.

Growth has stayed strong so far this year. The group’s sales rose by 56% to $11.4bn during the first quarter, while adjusted earnings were 16% higher.

What’s the risk?

One thing that’s stopped me from buying AstraZeneca shares in recent years has been the company’s poor cash generation. Mr Soriot’s spending spree has been financed mostly by borrowed cash – net debt has risen from under $5bn to $24bn since 2014.

If the company had continued down this path, then a dividend cut might have been needed. Fortunately, I can see signs that its cash-guzzling days may soon be in the past.

The group’s free cash flow (surplus cash generated by the business) rose from $3.6bn to $5.6bn in 2021. Broker forecasts suggest this figure will rise to more than $7bn in 2022 and could top $10bn in 2023.

Here’s what I’m going to do

It looks like the big investments are starting to produce the best result of all – cash. However, AstraZeneca shares are still trading on 19 times forecast earnings, with a dividend yield of just 2.3%.

That’s a significant premium to FTSE 100 rival GSK, whose shares currently trade on 14 times earnings, with a prospective yield of 3.1%.

Although its earnings are expected to rise more quickly than those of GSK over the next few years, I’m not convinced that will be enough to justify the stock’s premium.

To help me decide, I’ve done some number crunching. What I found is that for me, AstraZeneca shares are already getting close to their fair value. I don’t think there’s enough value left for me to buy after the stock’s recent rebound.

On the other hand, GSK looks more promising to me. I plan to take a look at this stock over the coming weeks to see whether it could qualify for a slot in my portfolio. I’ll report back here with my findings.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

7.5x earnings, £80.2m in net cash, and a big yield… what’s not to like about this UK stock?

This UK stock has a really strong net cash position relative to its size and its other metrics are very…

Read more »

Two male friends are out in Tynemouth, North East UK. They are walking on a sidewalk and pushing their baby sons in strollers. They are wearing warm clothing.
Investing For Beginners

My daughter could earn a £75,000 second income because we started an ISA at birth

Earning a second income is a dream for many Britons. By leveraging time, investors could make it a reality for…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

Could this trigger a stock market crash?

Dr James Fox takes a closer look at an alarming trend in the Far East that could have consequences for…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

What’s happening with the Jet2 share price?

The Jet2 share price has lost momentum after the tour operator said that customers were leaving their bookings to the…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Could the Chancellor’s Leeds Reforms trigger a bull market for UK stocks?

More competitive lending and greater interest in shares could help kick start growth for UK businesses. But could it also…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I think this AI stock could double before Palantir

Palantir stock is up almost 100% this year. As a result, it now sports a market cap of $350bn meaning…

Read more »

Elevated view over city of London skyline
Investing Articles

As the FTSE 100 hits an all-time high, is it time to reconsider the S&P 500?

Christopher Ruane explains why a surging FTSE 100 has not yet made him focus more on the potential of S&P…

Read more »

GSK scientist holding lab syringe
Investing Articles

The FTSE 100 sits at a record high. But some stocks still look dirt cheap!

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains…

Read more »